328 related articles for article (PubMed ID: 31129526)
1. fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsy.
Allendorfer JB; Nenert R; Bebin EM; Gaston TE; Grayson LE; Hernando KA; Houston JT; Hansen B; Szaflarski JP
Epilepsy Behav; 2019 Jul; 96():114-121. PubMed ID: 31129526
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy.
Nenert R; Allendorfer JB; Bebin EM; Gaston TE; Grayson LE; Houston JT; Szaflarski JP
Epilepsy Behav; 2020 Nov; 112():107297. PubMed ID: 32745959
[TBL] [Abstract][Full Text] [Related]
3. Effects of highly purified cannabidiol (CBD) on fMRI of working memory in treatment-resistant epilepsy.
Gaston TE; Allendorfer JB; Nair S; Bebin EM; Grayson LP; Martin RC; Szaflarski JP;
Epilepsy Behav; 2020 Nov; 112():107358. PubMed ID: 32871501
[TBL] [Abstract][Full Text] [Related]
4. Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy.
Gaston TE; Szaflarski M; Hansen B; Bebin EM; Szaflarski JP;
Epilepsy Behav; 2019 Jun; 95():10-17. PubMed ID: 31003195
[TBL] [Abstract][Full Text] [Related]
5. Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy.
Martin RC; Gaston TE; Thompson M; Ampah SB; Cutter G; Bebin EM; Szaflarski JP
Epilepsy Behav; 2019 Aug; 97():105-110. PubMed ID: 31220785
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.
Szaflarski JP; Bebin EM; Cutter G; DeWolfe J; Dure LS; Gaston TE; Kankirawatana P; Liu Y; Singh R; Standaert DG; Thomas AE; Ver Hoef LW;
Epilepsy Behav; 2018 Oct; 87():131-136. PubMed ID: 30100226
[TBL] [Abstract][Full Text] [Related]
7. Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.
Gaston TE; Bebin EM; Cutter GR; Ampah SB; Liu Y; Grayson LP; Szaflarski JP;
Epilepsy Behav; 2019 Sep; 98(Pt A):201-206. PubMed ID: 31382177
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.
Gaston TE; Ampah SB; Martina Bebin E; Grayson LP; Cutter GR; Hernando K; Szaflarski JP;
Epilepsy Behav; 2021 Apr; 117():107862. PubMed ID: 33667843
[TBL] [Abstract][Full Text] [Related]
9. A preliminary study of the effects of cannabidiol (CBD) on brain structure in patients with epilepsy.
Sharma AA; Nenert R; Allendorfer JB; Gaston TE; Grayson LP; Hernando K; Szaflarski JP
Epilepsy Behav Rep; 2019; 12():100341. PubMed ID: 32322816
[TBL] [Abstract][Full Text] [Related]
10. Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy.
Thompson MD; Martin RC; Grayson LP; Ampah SB; Cutter G; Szaflarski JP; Bebin EM
Epilepsy Behav; 2020 Oct; 111():107299. PubMed ID: 32759071
[TBL] [Abstract][Full Text] [Related]
11. The longitudinal effects of cannabidiol on brain temperature in patients with treatment-resistant epilepsy.
Sharma AA; Szaflarski JP
Epilepsy Behav; 2024 Feb; 151():109606. PubMed ID: 38199054
[TBL] [Abstract][Full Text] [Related]
12. Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol.
Szaflarski JP; Hernando K; Bebin EM; Gaston TE; Grayson LE; Ampah SB; Moreadith R
Epilepsy Behav; 2019 Jun; 95():131-136. PubMed ID: 31048098
[TBL] [Abstract][Full Text] [Related]
13. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.
O'Neill A; Wilson R; Blest-Hopley G; Annibale L; Colizzi M; Brammer M; Giampietro V; Bhattacharyya S
Psychol Med; 2021 Mar; 51(4):596-606. PubMed ID: 31994476
[TBL] [Abstract][Full Text] [Related]
14. Motivation by potential gains and losses affects control processes via different mechanisms in the attentional network.
Paschke LM; Walter H; Steimke R; Ludwig VU; Gaschler R; Schubert T; Stelzel C
Neuroimage; 2015 May; 111():549-61. PubMed ID: 25731995
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam.
Savage TE; Sourbron J; Bruno PL; Skirvin LA; Wolper ES; Anagnos CJ; Thiele EA
Epilepsy Res; 2020 Feb; 160():106263. PubMed ID: 31923763
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
[TBL] [Abstract][Full Text] [Related]
17. The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy.
Warren PP; Bebin EM; Nabors LB; Szaflarski JP
Neurocase; 2017; 23(5-6):287-291. PubMed ID: 29063814
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.
Szaflarski JP; Bebin EM; Comi AM; Patel AD; Joshi C; Checketts D; Beal JC; Laux LC; De Boer LM; Wong MH; Lopez M; Devinsky O; Lyons PD; Zentil PP; Wechsler R;
Epilepsia; 2018 Aug; 59(8):1540-1548. PubMed ID: 29998598
[TBL] [Abstract][Full Text] [Related]
19. Altered attention networks and DMN in refractory epilepsy: A resting-state functional and causal connectivity study.
Jiang LW; Qian RB; Fu XM; Zhang D; Peng N; Niu CS; Wang YH
Epilepsy Behav; 2018 Nov; 88():81-86. PubMed ID: 30243110
[TBL] [Abstract][Full Text] [Related]
20. Executive attention control and emotional responding in attention-deficit/hyperactivity disorder--A functional MRI study.
Hwang S; White SF; Nolan ZT; Craig Williams W; Sinclair S; Blair RJ
Neuroimage Clin; 2015; 9():545-54. PubMed ID: 26640766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
